Summary & Overview
HCPCS J2508: Injection, pegunigalsidase alfa-iwxj, 1 mg
HCPCS Level II code J2508 designates the injectable biologic pegunigalsidase alfa-iwxj, billed per 1 mg unit. This code is used for administration of an enzyme replacement therapy delivered intravenously for patients requiring this specific biologic agent. Nationally, accurate use of J2508 affects payment, prior authorization workflows, and access to specialty infusion services for medically indicated patients.
Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for this enzyme replacement product, typical sites of service where it is administered, and the coding conventions that drive claims processing. The publication provides benchmarking information where available, summarizes relevant policy and coverage considerations from major payers, and outlines billing considerations specific to a per-milligram HCPCS Level II injectable code.
This analysis is intended for a national audience of coding professionals, revenue cycle managers, and specialty clinicians. It highlights billing and documentation implications tied to unit-based reporting, common places-of-service for infusion therapies, and areas where payer policies commonly affect authorization and reimbursement outcomes.
Billing Code Overview
HCPCS Level II code J2508 describes an injection of pegunigalsidase alfa-iwxj, 1 mg, a recombinant enzyme replacement therapy formulation. The service type is injectable biologic therapy administered intravenously, typically provided in infusion centers, hospital outpatient departments, or specialty clinics depending on payer and clinical setting. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with confirmed Fabry disease receives regular intravenous enzyme replacement therapy using pegunigalsidase alfa. Typical patient: a 38-year-old male with classic Fabry disease presenting for scheduled outpatient infusion every two weeks. Prior to infusion, nursing staff verify identity, review pre-infusion vitals and allergy history, confirm consent, and review recent labs (renal function, liver enzymes). The medication J2508 is prepared by pharmacy in a sterile compounding area and delivered to the infusion suite. An infusion nurse starts an indwelling peripheral IV or accesses a port, administers pre-medications if prior infusion reactions occurred (e.g., antihistamine, corticosteroid), initiates infusion per manufacturer infusion rate guidelines, and monitors vital signs and infusion tolerance for adverse reactions. Post-infusion, the nurse documents dose administered, lot number, and any adverse events; disposes of any unused biologic per JW/JZ guidance; and schedules the next infusion. Typical site of service is an outpatient infusion center, physician office infusion suite, or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological wasted | Report when part of a single-use vial or dose is discarded and the discarded amount is documented |